Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276424 | 0.81 | HEXA (0.57) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5707657 | 0.81 | CES1 (0.57) | CASP3MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10100428 | 0.80 | TERT (0.47) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20979820 | 0.79 | CASP3 (0.50) | CASP3CDC25BMEN1KMT2AMAPT | |
| SCHEMBL15181275 | 0.78 | MEN1 (0.47) | CASP3MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8727685 | 0.78 | ALDH1A1 (0.45) | CASP3MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL27471585 | 0.78 | DPP4 (0.47) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL11036033 | 0.76 | RNASEH1 (0.56) | CASP3MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11711016 | 0.76 | CA12 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL11665542 | 0.75 | CA12 (0.43) | CASP3CDC25BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4016663-A1 | ELECTRODE MATERIAL FOR THE PRINTING OF POLYMER BATTERIES | Evonik Operations GmbH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | AMGEN INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-9889213-B2 | Multimodal imaging of fibrin | THE GENERAL HOSPITAL CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3077392-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | Amgen Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160199519-A1 | Multimodal Imaging of Fibrin | THE GENERAL HOSPITAL CORPORATION | 2016-07-14 | — | — | US | disclosed |
| US-9200017-B2 | Multimodal imaging of fibrin | THE GENERAL HOSPITAL CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2015084649-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | AMGEN INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084649-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | AMGEN INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008106104-A2 | ENVIRONMENTALLY SENSITIVE FLUOROPHORES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008023357-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-02-28 | — | — | WO | disclosed |
| EP-1037947-B1 | CYANINE DYES | AMERSHAM PLC (GB) | 2003-09-10 | — | — | EP | disclosed |
| US-6468730-B2 | DI- OR TRIHALO-SUBSTITUTED CARBOXY OR SULFONIC ACID STORAGE STABILIZER | FUJI PHOTO FILM CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-6348599-B1 | CYANINE DYES HAVING OVERALL POSITIVE CHARGE OF +2 TO +6 AND REACTIVE OR FUNCTIONAL GROUP PRESENT WHICH CAN REACT WITH FUNCTIONAL OR REACTIVE GROUP OF TARGET MOLECULE | NYCOMED AMERSHAM PLC (GB) | 2002-02-19 | — | — | US | disclosed |
| US-20020015926-A1 | IMAGE RECORDING MATERIAL | FUJIFILM CORPORATION (JP) | 2002-02-07 | — | — | US | disclosed |
| EP-1037947-A1 | CYANINE DYES | Nycomed Amersham plc (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999005221-A1 | CYANINE DYES | NYCOMED AMERSHAM PLC (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CASP3 50/4885CDC25B 1828/4885MEN1 3400/4885 |
| US-20160199519-A1 | Multimodal Imaging of Fibrin | FGB, F2, SERPINC1 | CASP3 1227/4885CDC25B 4650/4885MEN1 605/4885 |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | BCL9, NPM1, MLLT3 | CASP3 819/4885CDC25B 228/4885MEN1 220/4885 |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | BCL9, NPM1, MLLT3 | CASP3 819/4885CDC25B 228/4885MEN1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.